Results 171 to 180 of about 4,815,425 (278)

Non‐Alzheimer Aβ deposits in the human CNS: Implications with hypoxia and related conditions

Brain Pathology, EarlyView.
An Aβ deposit in a non‐Alzheimer's brain from an individual who experienced hypoxia/energy failure. Abstract We recently reported the deposition of Aβ in the frontal cortex of individuals who died of acute coronavirus disease 2019 (COVID‐19), or who did not have COVID‐19 but had respiratory distress, or infants with severe cardiac malformations.
Esma Karlovich, David S. Priemer, Charles Harker Rhodes, Daniel P. Perl, Kurenai Tanji, James E. Goldman   +5 more
wiley   +1 more source

Controversy -Should we give thrombolysis to patients with submassive pulmonary embolism?

, 2015
European Congres of the European Society of Emergency Medicine (EUSEM), oct 2015, Torino, Italie. Orateur: “-Controversy -Should we give thrombolysis to patients with submassive pulmonary embolism?
Verschuren, Franck, Controversy -Should we give thrombolysis to patients with submassive pulmonary embolism?   +1 more
core  

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

British Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Phase II Study of Cisplatin/Gemcitabine Plus Necitumumab for Squamous NSCLC After ICI‐Platinum Therapy (WJOG14120L)

Cancer Science, EarlyView.
WJOG14120L NESSIE evaluated cisplatin, gemcitabine, and necitumumab (CGN) as second‐line therapy after ICI‐based treatment in 46 patients with advanced squamous NSCLC. ORR was 26.1%, DCR 87.0%, and median PFS 4.4 months. Although the predefined ORR threshold was not met, CGN showed modest antitumor activity with manageable toxicity.
Hiroshige Yoshioka, Keita Mori, Nobuhisa Ishikawa, Hiroaki Kanemura, Koichi Azuma, Yukihiro Toi, Hiroshi Handa, Yosuke Tamura, Hiroaki Akamatsu, Haruko Daga, Masafumi Yamaguchi, Teppei Yamaguchi, Yuki Sato, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Takayasu Kurata   +15 more
wiley   +1 more source

Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs

Clinical Endocrinology, EarlyView.
ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams, Bonnie Grant, Richard Quinton, Channa N. Jayasena   +3 more
wiley   +1 more source

Musculoskeletal health among adults with cerebral palsy: A systematic review

Developmental Medicine &Child Neurology, EarlyView.
Abstract Aim To describe the burden of, and investigate prognostic factors for, osteoarthritis, osteopenia and/or osteoporosis, spondylosis, and fracture, and to investigate the effectiveness of protocols for monitoring musculoskeletal disorders and interventions for managing osteoarthritis in adults with cerebral palsy (CP).
Jennifer M. Ryan, Jessica Burke, Rachel Byrne, Emily Capellari, Christina M Marciniak, Maram Sofiany, Reuel Jalal, Mark Peterson, The Adult CP Clinical Practice Guideline Working Group, Jan Willem Gorter, Ashley Harris Whaley, Christine Imms   +11 more
wiley   +1 more source

Economic Burden of Overweight and Obesity in Sweden: Current Estimates and Future Projections

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Overweight and obesity are major public health challenges and well‐established risk factors for cardiovascular disease, cancer and premature mortality. We estimated the economic burden of overweight and obesity in Sweden in 2023 and projected the future economic burden in 2040 under alternative scenarios of increasing prevalence ...
Adam Fridhammar, Jovanna Dahlgren, Marije Galavazi, Lena Hjelm, Jonatan Dereke, Katarina Steen Carlsson   +5 more
wiley   +1 more source

Efficacy and safety of high doses of eltrombopag for treating adult immune thrombocytopenia: Results from a multicentre retrospective cohort study

British Journal of Haematology, EarlyView.
Salomé Dahan, Stéphanie Guillet, Olivier Fain, Delphine Gobert, Stéphane Cheze, Florent Broca, Bertrand Godeau, Marc Michel   +7 more
wiley   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou, Christoforos K. Travlos, Lucas Lage Marinho, Thomas A. Mavrakanas, João Pedro Ferreira, Abhinav Sharma   +5 more
wiley   +1 more source